Maky Zanganeh is an Iranian-American entrepreneur, billionaire, and biotechnology executive best known for her leadership at Summit Therapeutics. Her career spans healthcare innovation, cancer drug development, and major pharmaceutical business deals.
From studying dentistry in France to becoming one of the most influential women in biotechnology, Zanganeh has built a remarkable professional career.
Who Is Maky Zanganeh?
Maky Zanganeh, whose full name is Mahkam Zanganeh, was born in Iran in 1970.
She currently serves as Co-Chief Executive Officer and President of Summit Therapeutics, a biotechnology company focused on developing treatments for serious diseases.
Before entering the biotechnology industry, she trained as a dentist and worked in pediatric dentistry.
Her interests eventually shifted toward healthcare technology, business management, and pharmaceutical innovation.
Maky Zanganeh’s Early Life and Education
Zanganeh spent her early years in Iran before continuing her education in Germany and France.
She studied dental surgery at Louis Pasteur University in Strasbourg, France, where she earned her Doctor of Dental Surgery degree.
She later obtained a Master of Business Administration from Schiller International University.
Her combination of medical education and business training helped prepare her for leadership positions in the healthcare industry.
Maky Zanganeh’s Career at Pharmacyclics
One of Zanganeh’s most significant career achievements came through her work at Pharmacyclics, a pharmaceutical company specializing in cancer treatments.
She joined the company in 2008 and eventually became Chief Operating Officer.
During her leadership, Pharmacyclics helped advance ibrutinib, a treatment used for certain blood cancers.
She also played an important role in the company’s business development activities.
In 2015, pharmaceutical giant AbbVie acquired Pharmacyclics for approximately $21 billion.
The transaction became a major milestone in her professional career.
Maky Zanganeh and Summit Therapeutics
Zanganeh joined Summit Therapeutics in 2020 and became Co-CEO and President in July 2022.
Working alongside Robert Duggan, she has helped guide the company’s development strategy.
Summit’s major research focus includes ivonescimab, an investigational cancer treatment designed to target PD-1 and VEGF.
The company has conducted clinical trials investigating the drug’s potential in treating non-small cell lung cancer.
Zanganeh’s leadership combines scientific understanding with commercial strategy and pharmaceutical development experience.
What Is Maky Zanganeh’s Net Worth in 2026?
According to Forbes, Maky Zanganeh’s estimated net worth was approximately $1 billion as of October 30, 2026.
Much of her fortune comes from her ownership stake in Summit Therapeutics.
Forbes reported that she owned just under 5% of the company’s shares.
Her wealth can fluctuate because stock prices and investment valuations change over time.
Is Maky Zanganeh Married?
Maky Zanganeh is married to Robert Duggan, an American billionaire businessman and biotechnology investor.
According to Forbes, the couple married in 2024.
They also work together as co-chief executives of Summit Therapeutics.
Their shared professional interests include pharmaceutical development, business investment, and healthcare innovation.
Maky Zanganeh’s Achievements and Recognition
Throughout her career, Zanganeh has received recognition for her contributions to biotechnology.
She appeared on Forbes’ 2025 list of America’s Richest Self-Made Women.
In 2013, she received recognition from Fierce Biotech for her work in the pharmaceutical industry.
She also published her memoir, The Magic of Normal: Hope, Love, and Beyond, in 2025.
Today, Maky Zanganeh remains an important figure in biotechnology, with a career shaped by entrepreneurship, pharmaceutical innovation, and international business leadership.
